Amphotericin B® treatment causes QT prolongation in lung transplant-patients

Le résumé fourni par la source

We analysed changes of beat-to-beat cardiac activity during intensive care stay and therapeutic intervention (e.g. antimycotic therapy) of double lung transplanted recipients with a high resolution electrocardiogram. Obtained results may offer new insights in the development of alterations in cardiac electrical activity of critical ill patients. At 1000 Hz sampling rate the cardiac electric activity of 45 double lung transplanted recipients on ICU were analysed during their stay and inhalationtherapy with 50 mg of Amphotericin B®. The electrodes were fixed on the prepared skin for recording the leads I, II, III and reconstruct pursuant to Einthoven´s equation aVR, aVL, aVF, obtaining continuous ten-minute recordings (Lab System Pro - Bard electrophysiology U.S.A.). Results obtained from 45 Amphotericin B® treatments show irrespective of the prior QT range an increasing of the QT-interval additionally up to 21 ms (p < 0,05) from the beginning of the infusion. This variation was observed for two minutes of therapy and returns with a slow to their pre-value. Concerning QT prolongation the beat-to-beat duration increases too. Other ECG data remained unchanged during the time of treatment. Haemodynamic alterations could be detected after the onset of antimycotic treatment with Amphotericin® lung transplantation recipients. With regard to comorbidities of lung transplanted patients, it seems reasonable that changes in cardiac electric activity based on heart lung interactions in humans during their ICU stay and their origin might be observed even earlier. In contrast even minor circadian beat to beat variations might precede the occurrence of potentially life threatening arrhythmias.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.